Target Entity: Aster DM Super-Specialty Hospital (Sarjapur) Private Limited ("Sarjapur Entity")

Type of Deal: Acquisition through rights issue (intra-group transaction)

Stake/Capacity: 4,50,89,995 equity shares acquired, maintaining 100% shareholding of the Sarjapur Entity by Aster DM Healthcare Limited

Deal Value: ₹45,08,99,950/- (Rupees Forty-Five Crore Eight Lakh Ninety-Nine Thousand Nine Hundred Fifty Only)

Funding Source: Cash consideration

Financial Impact: Not disclosed in the document. The Sarjapur Entity is yet to commence its business operations.

Timeline: Transaction completed on June 18, 2026 with shares allotted on the same date

Strategic Rationale: The investment is being made for general corporate purposes of the Sarjapur entity

Approval Status: Completed and allotted on June 18, 2026. The transaction falls within related party transactions but is exempted from provisions as per Regulation 23(5) of SEBI Listing Regulations as it involves a holding company and wholly owned subsidiary.

Reference Regulation: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Additional Entity Details:

  • Date of incorporation: July 21, 2025
  • Authorized Share Capital: ₹153,55,00,000/- comprising:
  • 10,00,00,000 equity shares of ₹10/- each
  • 38,40,000 Series A compulsorily convertible preference shares of ₹50/- each
  • 68,70,000 Series B compulsorily convertible preference shares of ₹50/- each
  • Paid-up Share Capital: ₹50,10,00,000/- comprising 5,01,00,000 equity shares of ₹10/- each
  • Business: Healthcare services, specifically setting up and operating healthcare services in Bengaluru, Karnataka, India
  • Current status: Yet to commence business operations

Transaction Characteristics:

  • Executed at arm's length basis
  • Promoter/promoter group/group companies have no interest in Sarjapur Entity apart from the holding company's ownership
  • No governmental or regulatory approvals required